Alectinib reliable in early-stage ALK -favorable NSCLC

MADRID– In a video interview, Julia Rotow, MD, talked about favorable information from the ALINA research study in ALK– favorable non-small cell lung cancer provided at ESMO Congress.

The research study revealed that alectinib (Alecensa, Genentech) considerably enhanced DFS compared to chemotherapy in early-stage clients with resected ALK– favorable NSCLC.

” As we return home, I anticipate to see approvals in this area and truly ought to now be evaluating all of our early-stage clients not simply for EGFR, however likewise for ALK to get them optimum adjuvant treatment choices,” Rotow, scientific director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, informed Healio.

Referral:

• Solomon B, et al. Abstract LBA2. Provided at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Released by:

Include subject to email informs.

Get an e-mail when brand-new posts are published on

Please supply your e-mail address to get an e-mail when brand-new posts are published on

” data-action= subscribe>>.
Subscribe.

We were not able to process your demand. Please attempt once again later on. If you continue to have this concern please contact [email protected]

Back to Healio

Take Residences in Lung Cancer